These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38593221)

  • 1. Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome.
    Rao VK; Kulm E; Grossman J; Buchbinder D; Chong H; Bradt J; Webster S; Šedivá A; Dalm VA; Uzel G
    Blood Adv; 2024 Jun; 8(12):3092-3108. PubMed ID: 38593221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim analysis: Open-label extension study of leniolisib for patients with APDS.
    Rao VK; Kulm E; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Dalm VA; Trizzino A; Zharankova Y; Webster S; Orpia A; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Relan A; Holland SM; Lenardo MJ; Uzel G
    J Allergy Clin Immunol; 2024 Jan; 153(1):265-274.e9. PubMed ID: 37797893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
    Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
    Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
    Rao VK; Webster S; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Conlon N; Coulter T; Dalm VA; Trizzino A; Zharankova Y; Kulm E; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Kucher K; Relan A; Holland SM; Lenardo MJ; Uzel G
    Blood; 2023 Mar; 141(9):971-983. PubMed ID: 36399712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond.
    Cant AJ; Chandra A; Munro E; Rao VK; Lucas CL
    J Allergy Clin Immunol Pract; 2024 Jan; 12(1):69-78. PubMed ID: 37777067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leniolisib: First Approval.
    Duggan S; Al-Salama ZT
    Drugs; 2023 Jul; 83(10):943-948. PubMed ID: 37256490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective.
    Berglund LJ
    J Clin Immunol; 2023 Dec; 44(1):34. PubMed ID: 38148368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
    Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
    Michalovich D; Nejentsev S
    Front Immunol; 2018; 9():369. PubMed ID: 29535736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
    Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
    J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment.
    Lougaris V; Piane FL; Cancrini C; Conti F; Tommasini A; Badolato R; Trizzino A; Zecca M; De Rosa A; Barzaghi F; Pignata C
    Ital J Pediatr; 2024 May; 50(1):103. PubMed ID: 38769568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A qualitative study to explore the burden of disease in activated phosphoinositide 3-kinase delta syndrome (APDS).
    Hitchcock I; Skrobanski H; Matter E; Munro E; Whalen J; Nolthenius JT; Crocker-Buque A; Harrington A; Vandenberghe D; Acaster S; Williams K
    Orphanet J Rare Dis; 2024 May; 19(1):203. PubMed ID: 38760658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APDS patients with immune-complex vasculitis and resolution with leniolisib.
    Doroudchi MA; Stephens AV; Wang Z; Dhami J; Butte MJ
    Clin Immunol; 2024 May; 262():110176. PubMed ID: 38462154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated phosphoinositide 3-dinase delta syndrome (APDS): An update.
    Lougaris V; Cancrini C; Rivalta B; Castagnoli R; Giardino G; Volpi S; Leonardi L; La Torre F; Federici S; Corrente S; Cinicola BL; Soresina A; Marseglia GL; Cardinale F
    Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):69-72. PubMed ID: 35080319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ANCA vasculitis expands the spectrum of autoimmune manifestations of activated PI3 kinase δ syndrome.
    Sood AK; Francis O; Schworer SA; Johnson SM; Smith BD; Googe PB; Wu EY
    Front Pediatr; 2023; 11():1179788. PubMed ID: 37274825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
    Condliffe AM; Chandra A
    Front Immunol; 2018; 9():338. PubMed ID: 29556229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with acquired pure red cell aplasia respond to PI3Kδ inhibitor rapidly.
    Wang Z; Jiang B; Song L; Sun M; Li C; Li X; Zheng W; Tao Y; Sun Q; Qi J
    Am J Hematol; 2024 Jul; 99(7):1431-1433. PubMed ID: 38607227
    [No Abstract]   [Full Text] [Related]  

  • 18. Homeostatic and pathogenic roles of PI3Kδ in the human immune system.
    Sogkas G; Adriawan IR; Dubrowinskaja N; Atschekzei F; Schmidt RE
    Adv Immunol; 2020; 146():109-137. PubMed ID: 32327151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
    Diaz N; Juarez M; Cancrini C; Heeg M; Soler-Palacín P; Payne A; Johnston GI; Helmer E; Cain D; Mann J; Yuill D; Conti F; Di Cesare S; Ehl S; Garcia-Prat M; Maccari ME; Martín-Nalda A; Martínez-Gallo M; Moshous D; Santilli V; Semeraro M; Simonetti A; Suarez F; Cavazzana M; Kracker S
    J Immunol; 2020 Dec; 205(11):2979-2987. PubMed ID: 33115853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.
    Bloomfield M; Klocperk A; Zachova R; Milota T; Kanderova V; Sediva A
    Front Pediatr; 2021; 9():697706. PubMed ID: 34350147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.